SCHEMBL7403221

SCHEMBL7403221

Cc1cc(C)c(S(=O)(=O)NC(CNC(=O)C2=NOC(CCCCNc3ccccn3)C2)C(=O)O)c(C)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 20/20 1.00
ITGA2B P08514 17/20 1.00
ITGAV P06756 16/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7402257 0.89 ITGB3 (1.00) ITGB3ITGA2BITGAV
SCHEMBL7400624 0.89 ITGB3 (0.82) ITGB3ITGA2BITGAV
SCHEMBL7405151 0.87 ITGB3 (0.92) ITGB3ITGA2BITGAV
SCHEMBL8552846 0.86 ITGB3 (0.82) ITGB3ITGA2BITGAV
SCHEMBL7396344 0.85 ITGB3 (1.00) ITGB3ITGA2BITGAV
Trifluoroacetic Acid SCHEMBL7403079 0.85 ITGB3 (0.91) ITGB3ITGA2BITGAV
SCHEMBL7398015 0.85 ITGB3 (1.00) ITGB3ITGA2BITGAV
SCHEMBL7407563 0.84 ITGB3 (0.73) ITGB3ITGA2BITGAV
SCHEMBL7407553 0.84 ITGB3 (0.73) ITGB3ITGA2BITGAV
SCHEMBL7405981 0.84 ITGB3 (0.74) ITGB3ITGA2BITGAV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1996037492-A1 ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-11-28 WO claimed
US-6214834-B1 ANGIOGENESIS INHIBITORS; ANTIINFLAMMATORY AGENTS; ANTICANCER AGENTS DUPONT PHARMACEUTICALS COMPANY 2001-04-10 US disclosed
EP-0828737-A1 ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1998-03-18 EP disclosed
WO-1996037492-A1 ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-11-28 WO disclosed